One in three American are affected by cardiovascular disease (CVD) and as a result 800,000 people die each year due to CVD. Many of those at risk could have better outcomes as there are interventions for prevention and control. However, many at risk show no symptoms.
The first webinar in this series examines how to best use lipids and lipoproteins to assess cardiovascular risk. Diagnosing heart failure (HF), and understanding how new and emerging biomarkers for HF work, is the focus of the second webinar in the series. An informative and entertaining debate over which is more important when using cardiac troponin to assess chest pain patients – speed or accuracy—will be the focus of the final webinar in the series.
Beyond “Good” and “Bad” Cholesterol: Is it Time to Consider a Particle Alternative?
James Otvos, PhD, Founder, Executive Vice President and Chief Scientific Officer, LipoScience, Inc., Raleigh, NC
Using Novel Biomarkers to Diagnose and Manage Heart Failure Patients
Christopher deFilippi, MD, Associate Professor of Medicine, University of Maryland, Division of Cardiology, Baltimore, MD
Using cTn to Assess Chest Pain Patients: The Accuracy vs. Turnaround Time Debate
Kent Lewandrowski, MD, Pathologist, Associate Chief for Laboratory and Molecular Medicine, Massachusetts General Hospital, and Professor of Pathology, Harvard Medical School, Boston, MA
Alan H.B. Wu, PhD, Chief of Clinical Chemistry and Toxicology, San Francisco General Hospital; Professor of Laboratory Medicine, University of California, San Francisco, CA